Crown Bioscience to Hold Symposium on Precision Medicine and Translating Oncology Drug Discovery into Success in the Clinic
Crown Bioscience , a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, will be hosting a symposium at The Nucleus in Chesterford Research Park, UK, on Feb. 10, 2016.
The symposium, “Precision Medicine: Translating Oncology Drug Discovery into Success in the Clinic,” will focus on the implementation of translational technologies across the research and clinical communities to improve the development of drugs before entering clinical trials, to support clinical decisions and to maximize clinical value.
“Our goal is to create an opportunity for leading scientists to share the latest scientific approaches in immuno-oncology and combination therapeutic regimes to help speed the best candidates to clinical development,” said Jean-Pierre Wery, Ph.D. , president of Crown Bioscience.
As an end-to-end preclinical to clinical service provider and thought leader in translational oncology, CrownBio has made a significant investment to improving the knowledge of the scientific community about translational platforms. The company has assembled a notable line-up of eight industry experts, including Dr. Gary Middleton , professor of medical oncology at University of Birmingham, and Dr. Thomas Mehrling , managing director of Mundipharma-EDO GmbH. The symposium will also feature CrownBio’s Dr. Rajendra Kumari , chief scientific officer, and Dr. Eric Murphy , global scientific director for translational oncology.
The event will be free to attend, but there are a limited number of places. To register, send an email to email@example.com with a request to join the event. For more information about the symposium and Crown Bioscience’s commitment to improving clinical outcomes, visit www.crownbio.com/news/events .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development service company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com .
For Crown Bioscience Inc.
Lea Studer, +1-308-237-5567
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
NY-MADISON-REALTY17.11.2017 17:22 | pressemeddelelse
Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn
NCARDIA17.11.2017 13:33 | pressemeddelelse
Ncardia Announces Completion of €10.5M Investment Round
VOCALINK17.11.2017 10:37 | pressemeddelelse
Double Win for Vocalink at the 2017 Payments Awards
ENVION-AG17.11.2017 10:02 | pressemeddelelse
Envion AG: Start-up from the Heart of Berlin Has Pioneered Decentralized Mobile Mining by Combining Blockchain with Regenerative Energy
CHUGAI-PHARMACEUTICAL17.11.2017 00:32 | pressemeddelelse
Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors
PACIFIC-DRILLING-S.A.16.11.2017 23:10 | pressemeddelelse
Pacific Drilling Receives Approval of First Day Motions
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum